T-Cell Lymphomas Drugs Development Market Report 2022: Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

·2 min read

DUBLIN, May 23, 2022--(BUSINESS WIRE)--The "T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the T-Cell Lymphomas pipeline landscape.

The report provides comprehensive information on the therapeutics under development for T-Cell Lymphomas, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of T-Cell Lymphomas

  • The pipeline guide reviews pipeline therapeutics for T-Cell Lymphomas by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities

  • The pipeline guide reviews key companies involved in T-Cell Lymphomas therapeutics and enlists all their major and minor projects

  • The pipeline guide evaluates T-Cell Lymphomas therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects

  • The pipeline guide reviews latest news related to pipeline therapeutics for T-Cell Lymphomas

Key Topics Covered:

  • Introduction

  • Report Coverage

  • Indication - Overview

  • Indication - Therapeutics Development

  • Pipeline Overview

  • Pipeline by Companies

  • Pipeline by Universities/Institutes

  • Products under Development by Companies

  • Products under Development by Universities/Institutes

  • Indication - Therapeutics Assessment

  • Assessment by Target

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

  • Indication - Companies Involved in Therapeutics Development

  • Indication - Drug Profiles

  • Indication - Dormant Projects

  • Indication - Discontinued Products

  • Indication - Product Development Milestones

  • Featured News & Press Releases

  • Appendix

For more information about this report visit https://www.researchandmarkets.com/r/wu11zv

View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005822/en/


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900